{"id":"W4393078914","doi":"10.1016/j.ejca.2024.113608","title":"Neoadjuvant pembrolizumab or placebo + chemotherapy, followed by adjuvant pembrolizumab or placebo plus endocrine therapy for early-stage high-risk ER+/HER2– breast cancer: Results from the phase 3 KEYNOTE-756 study","year":2024,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Pembrolizumab; Medicine; Stage (stratigraphy); Breast cancer; Oncology; Placebo; Chemotherapy; Internal medicine; Adjuvant; Adjuvant chemotherapy; Cancer; Immunotherapy; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.003173539,0.0009529825,0.001632858,0.0003452313,0.0004494945,0.0005199654,0.00145415,0.000113408,0.004233483],"category_scores_gemma":[0.0005203978,0.0005295828,0.0006663284,0.0008527707,0.0003150399,0.0004032856,0.0001945699,0.002173529,0.0000670615],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001593351,"about_ca_system_score_gemma":0.003784445,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.006867269,"about_ca_topic_score_gemma":0.001477726,"domain_scores_codex":[0.9914417,0.001565129,0.00215534,0.001188772,0.002296985,0.001352037],"domain_scores_gemma":[0.9942819,0.001646708,0.001060424,0.001271902,0.0009108832,0.0008281061],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"not_applicable","study_design_scores_codex":[0.4388661,0.001109597,0.001260128,0.000154176,0.003214304,0.00534561,0.008055466,0.0004470774,0.003330913,0.000004056543,0.2114371,0.3267755],"study_design_scores_gemma":[0.2888669,0.01708852,0.01534429,0.002578963,0.001235934,0.0007414629,0.002159992,0.001829261,0.003688445,0.00001532941,0.6654174,0.00103351],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9364786,0.02668742,0.000922936,0.01669423,0.003150304,0.005239422,0.009968844,0.0002176223,0.0006406115],"genre_scores_gemma":[0.943818,0.02766734,0.0002385649,0.00123961,0.005664702,0.0003099218,0.00006565468,0.0005468116,0.02044943],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4539803,"threshold_uncertainty_score":0.9997461,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04050519310740351,"score_gpt":0.3783540340905074,"score_spread":0.3378488409831039,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}